Myriad Genetics, Inc.

622 articles with Myriad Genetics, Inc.

• Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

  6/28/2022

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable society.

• Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

  6/23/2022

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company, to integrate Myriad’s full line of genetic tests with Epic’s expansive network of 600,000 physicians and more than 250 million patients.

• Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

  6/9/2022

  Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation and growth plan during a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference.

• Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

  5/26/2022

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment.

• Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

  5/5/2022

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its first quarter 2022.

• Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

  5/4/2022

  Paul J. Diaz, president and CEO of Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:20 p.m. EDT.

• Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

  5/3/2022

  Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio.

• Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

  4/28/2022

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT.

• Immunovia appoints Jeff Borcherding, previously Chief Marketing Officer at Myriad Genetics, to lead Immunovia's US business

  3/28/2022

  Immunovia has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc. He joins from Myriad Genetics, one of the leading diagnostic companies in the US, where he was Chief Marketing Officer.

• Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

  3/14/2022

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients.

• Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

  3/12/2022

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the U.S. Food and Drug Administration has approved Myriad’s BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated HER2 negative, high-risk early-stage breast cancer who may benefit from Lynparza®.

• Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

  3/8/2022

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, has been recognized on Fast Company’s annual list of the World’s Most Innovative Companies for 2022.

• Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

  3/2/2022

  Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 8, 2022 at 9:50 a.m. ET.

• Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

  2/24/2022

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its fourth quarter and year ended Dec. 31, 2021.

• New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

  2/23/2022

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the peer-reviewed journal Psychiatry Research has published a new analysis of GeneSight® Psychotropic, the company’s mental health medication test, in its Feb. 2022 edition.

• Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

  2/16/2022

  Myriad Genetics, Inc. will hold its 2021 fourth-quarter earnings conference call on Thursday, February 24, 2022 at 4:30 p.m. ET. T

• Myriad Genetics to Present at Two Upcoming Healthcare Conferences

  2/14/2022

  On Feb. 17, 2022, R. Bryan Riggsbee, chief financial officer, will participate in a fireside chat at the virtual BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference at 12 p.m. ET.

• Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

  1/5/2022

  Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022.

• Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

  1/4/2022

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer, after more than 19 years of distinguished service.

• 

  BioSpace Movers & Shakers, Dec. 24

  12/24/2021

  With all eyes on a new year, life sciences companies and organizations are making last-minute appointments to strengthen their leadership teams and board with these Movers & Shakers.